Other bispecific antibodies include amivantamab, an EGFR/c-Met bispecific antibody for non-small-cell lung cancer (NSCLC) treatment, and tebentafusp, a novel gp100×CD3 for treatment of HLA-A*02:01 positive non-resectable or metastatic uveal melanoma. Here, MET is linked to non-small cell lung carcinoma.